The ECDC, the infectious diseases watchdog, has asked for scientists to join its new panel on RSV as Europe begins to vaccinate its most vulnerable adults.

The winter respiratory virus season is still in full swing, with Illinois under a "high" alert level from the Centers for Disease Control and Prevention. Among the viruses circulating most are ...

A phase 3b trial showed adjuvanted RSVPreF3 vaccination was immunogenic and safe for younger adults with chronic conditions at increased risk for RSV disease.

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the Arexvy vaccine.

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making.

Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...

RSV vaccination for adults aged 60+ could prevent significant LRTD cases, hospitalizations, and deaths over five years. A 5-percentage-point increase in vaccine uptake could avert over 222,000 LRTD ...

The FDA has approved a third respiratory syncytial virus vaccine for high-risk adults aged younger than 50 years — a ...

New real-world data confirm the RSV vaccine offers strong protection for older adults across two winters, but highlight weaker responses in those with compromised immunity and cardiovascular disease.

RSV in older adults remains a growing public health concern. Read more about surveillance gaps, vaccination policy, and prevention needs.